ZNTL
Price:
$3.235
Market Cap:
$230.54M
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, ...[Read more]
Industry
Biotechnology
IPO Date
2020-04-03
Stock Exchange
NASDAQ
Ticker
ZNTL
According to Zentalis Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 229.68M. This represents a change of -67.27% compared to the average of 701.67M of the last 4 quarters.
The mean historical Enterprise Value of Zentalis Pharmaceuticals, Inc. over the last ten years is 1.48B. The current 229.68M Enterprise Value has changed 1.45% with respect to the historical average. Over the past ten years (40 quarters), ZNTL's Enterprise Value was at its highest in in the December 2021 quarter at 3.77B. The Enterprise Value was at its lowest in in the June 2019 quarter at 0.
Average
1.48B
Median
1.04B
Minimum
393.79M
Maximum
3.57B
Discovering the peaks and valleys of Zentalis Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 176.88%
Maximum Annual Enterprise Value = 3.57B
Minimum Annual Increase = -70.16%
Minimum Annual Enterprise Value = 393.79M
Year | Enterprise Value | Change |
---|---|---|
2023 | 1.01B | -5.68% |
2022 | 1.07B | -70.16% |
2021 | 3.57B | 71.96% |
2020 | 2.08B | 176.88% |
2019 | 750.74M | 90.64% |
The current Enterprise Value of Zentalis Pharmaceuticals, Inc. (ZNTL) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
1.88B
5-year avg
1.70B
10-year avg
1.48B
Zentalis Pharmaceuticals, Inc.’s Enterprise Value is less than Sana Biotechnology, Inc. (353.45M), less than Olema Pharmaceuticals, Inc. (325.64M), less than Cullinan Oncology, Inc. (606.95M), greater than aTyr Pharma, Inc. (138.44M), less than Gracell Biotechnologies Inc. (5.66B), greater than Theseus Pharmaceuticals, Inc. (138.26M), less than Monte Rosa Therapeutics, Inc. (351.25M), less than Design Therapeutics, Inc. (324.66M), less than Erasca, Inc. (712.08M), less than Day One Biopharmaceuticals, Inc. (847.48M), greater than Inozyme Pharma, Inc. (212.37M), less than Syndax Pharmaceuticals, Inc. (974.92M), less than Protagonist Therapeutics, Inc. (2.23B), less than Revolution Medicines, Inc. (7.90B), less than Blueprint Medicines Corporation (6.09B), less than Kymera Therapeutics, Inc. (2.61B), greater than iTeos Therapeutics, Inc. (155.06M), less than Icosavax, Inc. (713.87M), less than Mirati Therapeutics, Inc. (3.91B), less than VectivBio Holding AG (848.58M), less than Annexon, Inc. (503.29M),
Company | Enterprise Value | Market cap |
---|---|---|
353.45M | $384.36M | |
325.64M | $359.83M | |
606.95M | $706.59M | |
138.44M | $131.12M | |
5.66B | $989.87M | |
138.26M | $181.50M | |
351.25M | $433.13M | |
324.66M | $352.47M | |
712.08M | $728.02M | |
847.48M | $1.27B | |
212.37M | $190.15M | |
974.92M | $1.11B | |
2.23B | $2.35B | |
7.90B | $8.02B | |
6.09B | $5.71B | |
2.61B | $2.64B | |
155.06M | $273.27M | |
713.87M | $769.04M | |
3.91B | $4.12B | |
848.58M | $1.06B | |
503.29M | $553.22M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Zentalis Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Zentalis Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Zentalis Pharmaceuticals, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Zentalis Pharmaceuticals, Inc. (ZNTL)?
What is the 3-year average Enterprise Value for Zentalis Pharmaceuticals, Inc. (ZNTL)?
What is the 5-year average Enterprise Value for Zentalis Pharmaceuticals, Inc. (ZNTL)?
How does the current Enterprise Value for Zentalis Pharmaceuticals, Inc. (ZNTL) compare to its historical average?